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Sphingolipids are ubiquitous in eukaryotic cells where they have been attributed a plethora of functions from the formation of
structural domains to polarized cellular traﬃcking and signal transduction. Recent research has identified and characterised many
of the key enzymes involved in sphingolipid metabolism and this has led to a heightened interest in the possibility of targeting these
processes for therapies against cancers, Alzheimer’s disease, and numerous important human pathogens. In this paper we outline
themajor pathways in eukaryotic sphingolipidmetabolism and discuss these in relation to disease and therapy for both chronic and
infectious conditions.
1. Introduction
Sphingolipids are a class of natural products that were first
characterised by the German-born chemist and clinician
Johann L. W. Thudichum in 1884. They consist of an sphin-
goid base backbone, for example sphingosine, that can be N-
acylated with fatty acids forming ceramides. To these lipid
anchors is attached a variety of charged, neutral, phosphory-
lated and/or glycosylated moieties forming complex sphin-
golipids, for example phosphorylcholine to make the most
abundant mammalian sphingolipid, sphingomyelin. These
moieties result in both polar and nonpolar regions giving the
molecules an amphipathic character which accounts for their
tendency to aggregate into membranous structures. Further-
more, the divergence encountered in their chemical struc-
tures allows them to play distinctive roles within cellular
metabolism (Figure 1) [1, 2].
Sphingolipids are ubiquitous and essential structural
components of eukaryotic membranes [3] as well as some
prokaryotic organisms and viruses [2]. They are found pre-
dominantly in the outer leaflet of the plasma membrane [4],
the lumen of intracellular organelles [5], and lipoproteins
[2]. Sphingolipids (most notably ceramide) are also bioactive
signalling molecules that control a plethora of cellular events
including signal transduction, cell growth, diﬀerentiation,
and apoptosis [6–10]. In addition, their role in protein kinase
C regulation has more recently been elucidated [11]. It is
noteworthy that some sphingolipid metabolites can exhibit
both structural and signalling functionalities. For example,
glycosphingolipids have been reported to be involved in cell-
ular recognition complexes, for example, blood group anti-
gens, cell adhesion, and the regulation of cell growth [4].
Over the last decade, there has been an exponential in-
crease in the study of sphingolipids. However, the investiga-
tion and deciphering of the functions of each specific sphin-
golipid remains challenging due to the complexity in sph-
ingolipid metabolic interconnection, their varied biophysical
properties (neutral or charged), the hydrophobic nature of
the enzymes involved, and the presence of multiple pathways
that can operate in parallel [12]. The interaction of sphin-
golipid biosynthesis with other cellular metabolic pathways,
for example glycerolipid metabolism, introduces another
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Figure 1: (a) The chemical structures of sphingosine and C18-ceramide; (b) the lipids isolated by Thudichum.
layer of complexity and the cellular role of an individual
sphingolipid could be defined as amultidimensional in terms
of subcellular localisation, regulation and mechanism of ac-
tion(s) [12].
Whilst the scientific literature has been enriched by arti-
cles focused on structural diversity [13–18] and cellular me-
tabolism [2, 8–10, 12, 19–21], this paper focuses on the key
enzymes involved in the regulation of ceramide, a central
sphingolipid and a key bioactive molecule [12]. To this end
we discuss the roles of these enzymes in the regulation of bio-
synthesis, and in the recycling, salvage, and degradation of
complex sphingolipids, in mammalian, fungal and proto-
zoan systems. In addition, we relate these observations to dis-
ease and potential therapies.
2. Sphingolipid Metabolism
Sphingolipid metabolism is a critical cell process [22] con-
stituting a highly complex network of interconnected path-
ways, with ceramide (and to a lesser degree dihydroceram-
ide) occupying a central position in both biosynthesis and
catabolism. Therefore, this simple but highly bioactive sph-
ingolipid represents a metabolic hub [12]. In terms of ceram-
ide, the routes of formation can be grouped into either de
novo synthesis; or recycling, salvage, and degradation (Figure
2). Sphingolipid metabolism has been extensively studied in
mammalian and fungal systems, where many of the enzymes
involved have been identified and characterised. Conse-
quently, the mammalian pathways will be used as the refer-
ence model in the following discussion.
2.1. De Novo Synthesis. The first step in the de novo bi-
osynthesis of sphingolipids is the condensation of serine
and palmitoyl CoA, a reaction catalysed by the normally
rate-limiting serine palmitoyltransferase (SPT, EC 2.3.1.50)
to produce 3-ketodihydrosphingosine [23]. SPTs are mem-
bers of the pyridoxal 5′-phosphate-dependent α-ox-
oamine synthase family who share a conserved motif
(T[FL][GTS]K[SAG][FLV]G) around the PLP-binding ly-
sine (in bold). The mammalian SPTs [23] (and those of other
eukaryotes [24, 25]) are membrane bound in the endoplas-
mic reticulum as a heterodimer of subunits LCB1 and LCB2
(∼53 and∼63 kDa); these are both type I integral membrane
proteins sharing ∼20% identity. The bacterial SPT is ∼30%
identical to both mammalian LCB1 and LCB2 at the amino
acid level and has the conserved lysine residue in the PLP-
binding motif, however the soluble 45 kDa protein forms
active homodimers [26]. Palmitoyl-CoA functions as the
best substrate of mammalian SPT in vitro, while it is also the
dominant acyl-CoA in vivo, and thus the sphingoid bases
from mammalian cells are predominantly C16 [23]. In con-
trast, the enzyme from the bacteria Sphingomonas wittichii
utilises stearoyl-CoA most eﬃciently [27]. A third subunit
increasing enzyme activity has been identified in Saccharo-
myces cerevisiae [28] and more recently 2 nonhomologous
but functionally related proteins have been characterised in
a mammalian system [29]. Furthermore, these additional
subunits confer distinct acyl-CoA substrate specificities to
the mammalian SPT thus explaining the diversity of long
chain bases found in mammals [30]. As the “gatekeeper” of
sphingolipid biosynthesis, loss of SPT has a catastrophic ef-
fect on mammalian cell viability with a partial loss of SPT
function seen in the inherited progressive disorder, Heredita-
ry Sensory Neuropathy type I (HSN1) [23]. The molecular
basis of this condition is discussed later in this paper.
Following sphinganine (dihydrosphingosine) formation,
metabolic diﬀerences are encountered. Whilst in fungi and
higher plants sphinganine is hydroxylated to phytosphingo-
sine then acylated to produce phytoceramide, in animal cells
sphinganine is acylated to dihydroceramide which is later
desaturated to form ceramide [31]. Ceramide (or phytoce-
ramide), a central sphingolipid, is then transported from the
ER to the Golgi apparatus where further synthesis of complex
sphingolipids takes place [7, 19, 20, 32]. Ceramide can be
phosphorylated by ceramide kinase [33], glycosylated by
glucosyl or galactosyl ceramide synthases [34], or acquire a
variety of neutral or charged head groups to form various
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Figure 2: A simplified diagram of sphingolipid metabolism in mammals. The key regulatory synthetic steps are indicated by the “traﬃc
light” symbols. SPT: Serine Palmitoyltransferase; 3-KSR: 3-Ketosphingosine Reductase; CerS: Ceramide Synthase; CDase: Ceramidase; CDes:
Ceramide Desaturase; SMS: Sphingomyelin Synthase; SMase: Sphingomyelinase; CK: Ceramide Kinase; GCS: Glucosylceramide Synthase;
GCase: Glycosidases; SK: Sphingosine Kinase; SPP: Sphingosine-1-Phosphate Phosphatase; S1P: Sphingosine-1-Phosphate.
complex phosphosphingolipids depending on the host or-
ganism. For example, in animal cells ceramide is a substrate
for sphingomyelin (SM) synthase to produce SM [35]. In
contrast, fungi and higher plants utilise phytoceramide to
produce inositol phosphorylceramide (IPC) as their princi-
pal phosphosphingolipid, a reaction catalysed by IPC syn-
thase [36, 37]. In these organisms IPC is later glycosylated
to produce more complex phosphosphingolipids, for exam-
ple, mannose-IPC (MIPC), in yeast [38, 39]. Finally, the pro-
tozoa (exemplified by the Kinetoplastidae) represent a dis-
tinct third group in which ceramide [21] acquires a phos-
phorylinositol head group from phosphatidylinositol (PI) to
produce IPC via IPC synthase [40] (Figure 3).
The synthesis of complex sphingolipids such as SM are
key regulatory synthetic steps, as the rate of synthesis not
only decreases the amount of ceramide, but also indirectly in-
creases the total amount of ceramide-containing molecules
that potentially could be degraded/catabolised to form cer-
amide.
Importantly, in such biosynthetic steps the evolutionarily
divergent SM and IPC synthases are central in controlling
the delicate balance of glycerolipids (PI/PC in and diacyl-
glycerol-DAG out) on one hand, and sphingolipids (phyto-
ceramide/ceramide in and IPC/SM out) on the other. There-
fore, these enzymes have an important role as regulators of
proapoptotic ceramide and promitogenic DAG [41]. In addi-
tion to a mitogenic role, DAG has also been attributed to
play a role in several enzyme activation and regulatory func-
tions [1, 2]. Notably, IPC synthase inhibitors are acutely fun-
gicidal, with the accumulation of ceramide proposed to in-
duce apoptosis [42]. Thus this enzyme represents an attrac-
tive target for antifungals and more recently this has been
extended to the kinetoplastid protozoa [43, 44].
2.2. Recycling, Salvage, andDegradation. In addition to the de
novo synthesis, the recycling, salvage, and degradation path-
ways modulate cellular levels of sphingolipids. These path-
ways operate in the direction of ceramide regeneration from
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complex sphingolipid reservoirs, for example glycosphin-
golipids (GSLs) and (SMs), through the action of specific
hydrolases and phosphodiesterases.
Sphingolipid recycling can be categorised as either lyso-
somal or nonlysosomal degradation. In lysosomal degrada-
tion, catabolism of GSLs occurs as sugar residues are cleaved
leading to the formation of glucosylceramide and galactosyl-
ceramide. In turn, specific β-glucosidases and galactosidases
hydrolyse these lipids to form ceramide which can then be
subsequently deacylated by an acid ceramidases to form sph-
ingosine [12, 45], which can then be salvaged to form ceram-
ide by reacylation. Defects in the function of these enzymes
lead to a variety of lysosomal storage disorders such as
Gaucher, Sandhoﬀ, and Tay-Sachs diseases, resulting from
the impairment of membrane degradation [46]. This will be
discussed in more detail later.
Degradation of sphingolipids is a necessary part of main-
taining lipid homeostasis, thus SM levels are maintained
by catabolic action of sphingomyelinases (SMases), either
neutral or acidic, releasing ceramide and the corresponding
headgroup, phosphorylcholine in the case of SM. Acid sph-
ingomyelinase (aSMase) was the first cloned human SMase
and was initially assumed to be not muchmore than a house-
keeping gene with a prominent role in the turnover of sphin-
gomyelin in the lysosome. However, unusually aSMase has
revealed itself to encode two unique enzymes through the
diﬀerential traﬃcking of a single-protein precursor [47]. In
addition to the commonly studied lysosomal aSMase, an
alternative form is secreted extracellularly and may have a
role in the nonlysosomal hydrolysis of SM both in the outer
leaflet of the plasma membrane and in lipoproteins in the
bloodstream [48]. These studies indicate that ceramide pro-
duction by sphingolipid hydrolysis in diﬀerent cellular or ex-
tracellular locations may provide diﬀerent metabolic eﬀects
and biological impacts. Indeed, the nonlysosomal degrada-
tion of SM is catalysed by neutral and alkaline SMases in a
variety of intracellular and extracellular locations. The least
studied of these SMases, the alkaline SMase (Alk-SMase), is
highly tissue specific with trypsin resistance and bile salt de-
pendency and has a key role in the dietary acquisition of cera-
mide by digesting SM in the gut [49]. Notably, animal stud-
ies have shown Alk-SMase is specifically down regulated in
colon cancer, while membrane SM accumulates. The sup-
plementation of dietary SM can prevent the promotion of
further colonic tumors [50].
SMases are commonly activated by growth factors, cyto-
kines, chemotherapeutic agents, irradiation and nutrient re-
moval [51], and though they can diﬀer in their subcellular
localisation and tissue specificity, all are thought to regulate
the local ceramide concentration and any corresponding
stress-induced responses [52]. Ceramide and associated met-
abolites, such as sphingosine-1-phosphate, are known to
function as second messengers, stimulating various biolog-
ical activities in mammalian cells, including the activation
of protein-kinases and/or protein-phosphatases 2A [53].
Increased levels of ceramides can exert antiproliferation ef-
fects, induce apotosis, and play major roles in mitogenesis
and endocytosis. There is a growing body of evidence
that suggests Mg2+-dependent neutral sphingomyelinases
(nSMases) are the major source for stress-induced ceramide
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production [51]. nSMases are ubiquitously expressed in
mammalian cells, predominately membrane bound on the
outer leaflet of the plasma membrane where most of the SM
is located [52]. Other mammalian nSMases localise to the
ER, where the predicted low abundance of SM has led to
speculation that they may have additional lipid substrates
such as lyso-platelet-activating factor [54]. In all cases of
sphingolipid catabolism, the released ceramide can be either
recycled into sphingolipid synthesis or degraded to sphin-
gosine [12, 45]. The resultant sphingosine, produced from
either pathway, is either recycled into sphingolipid biosyn-
thesis or phosphorylated by a cytosolic sphingosine kinase
(SK) yielding sphingosine-1-phosphate (S1P). S1P can itself
be dephosphorylated back to sphingosine or irreversibly
degraded by S1P lyase into the nonsphingolipid species etha-
nolamine phosphate and hexadecenal, representing a unique
exit point from the sphingolipid metabolic pathway [12, 45].
In fact this is the mechanism by which the kinetoplastid
Leishmania obtain ethanolamine [21].
Another kinetoplastid, Trypanosoma brucei, has shown
that an ER nSMase directly involved in sphingolipid catabo-
lism is essential because its formation of ceramide is required
for post-Golgi sorting and deposition of the essential gly-
cosylphosphatidylinositol-anchored variant surface glyco-
protein on the cell surface [55]. Similarly, the Leishmania
nSMase is essential for virulence and, whilst able to catabolise
inositol phosphorylceramide (IPC), demonstrated greater
activity with SM [56].
The corresponding yeast nSMase homologue (Isc1) is
also capable of IPC catabolism, generating ceramide. During
early growth Isc1p resides in the ER, but in late logarithmic
growth it is found in the outer leaflet of the mitochondria,
where the resulting ceramide formation plays a crucial role in
the reprogramming of mitochondrial gene expression dur-
ing the transition from anaerobic to aerobic metabolism,
coupled with a change in carbon source, that is, glucose to
ethanol [57, 58].
3. Ceramide Homeostasis
As discussed, ceramides are central intermediates of sph-
ingolipid metabolism. In addition to forming the basis of
complex sphingolipids, ceramide is a bioactive molecule that
regulates a myriad of cellular pathways including apoptosis,
cell senescence, the cell cycle, and diﬀerentiation [59]. In ad-
dition, this lipid species is involved in the cell response to
stress challenge. Notably, several anticancer drugs, for ex-
ample, etoposide and daunorubicin, have been found to
function by elevating the level of cellular ceramide triggering
apoptosis [60–63]. The apoptotic role of ceramide [64, 65]
contrasts with that of the mitogenic agonist DAG. Whilst the
former stimulates signal transduction pathways associated
with cell death or growth inhibition, DAG activates the var-
ious isoforms of protein kinase C associated with cell growth
and survival. Thus, ceramide and DAG generation may regu-
late cellular homeostasis by inducing death and growth, res-
pectively. Given that ceramide and DAG are a substrate and
a byproduct, respectively, of SM and IPC synthases, these
enzymes are hypothesized to play a central role in homeosta-
sis [9].
Recently, a human SM synthase-related protein has been
shown to function as a ceramide sensor [66] with a crucial
role in protecting cells against ceramide-induced cell death.
Disruption of this sensor leads to ceramide accumulation
in the endoplasmic reticulum and mitochondrial-mediated
apoptosis. This process is suppressed by targeting a cerami-
dase to mitochondria indicating that transfer of ceramide
from the endoplasmic reticulum to mitochondria, via an un-
knownmechanism, is a key step in committing cells to death.
The presence of a mitochondrial ceramide synthase has also
been reported and hypothesized to play a role in this apoptot-
ic process [67]. Together, these findings provide mechanistic
evidence for the proapoptotic accumulation of ceramide in
the mitochondria and demonstrate that the regulation of
ceramide homeostasis is a vital cellular function.
4. Defects in Sphingolipid Metabolism
Despite sphingolipids being minor components in some
cells, their accumulation in certain cells and tissues forms the
basis of many human diseases.
4.1. Sphingolipidoses. Defects in sphingolipid catabolism,
that is, lipid hydrolases, form the basis of a wide variety of
human diseases. These diseases, collectively known as sphin-
golipidoses (Figure 4), belong to the lysosomal storage dis-
eases and are inherited disorders characterised by accumula-
tions in specific lipids in certain tissues and/or organs.
The most common is Gaucher disease, in which gluco-
sylceramide accumulates due to a deficiency of glucosylcera-
mide-β-glucosidase, causing changes in the specialisedmem-
brane microdomains termed lipid rafts. This in turn seems
to impair lipid and protein sorting and consequently causes
the pathology characterising this disorder. For example, lipid
rafts are necessary for correct insulin signalling, and a per-
turbed lipid raft composition impairs insulin signalling lead-
ing to the insulin-resistance observed in patients with Gau-
cher disease [68, 69].
Fabry disease is an X-chromosomal-linked inherited de-
ficiency of lysosomal α-galactosidase A, causing deposition
of globotriaosylceramide in the lysosomes of endothelial,
perithelial and smooth-muscle cells of blood vessels. This
leads to renal, cardiac and/or cerebral complications and,
most commonly, death before the age of 50 [70, 71].
Tay-Sachs disease or GM2-gangliosidosis comes in vari-
ous forms, the most extreme, infantile form being caused by
defects in β-hexosaminidase A and has a high heterozygote
frequency (1 : 27) among Ashkenazi Jews. This condition
leads to death between the second and fourth years of life
[72, 73].
Sandhoﬀ disease is characterized by storage of negatively
charged glycolipids and elevation of uncharged glycolipids.
This disease has various clinical forms, infantile, juvenile,
and adult, all with varying pathological manifestations, in-
cluding a chronic variant similar to Tay-Sachs disease [74,
75].
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Figure 4: Defects in mammalian sphingolipid catabolism and their associated sphingolipidoses. The enzymes responsible are indicated at
the glycosidic linkages on which they act.
The inherited Niemann-Pick disease (types A and B) is
characterised by a deficiency in the lysosomal acidic SMase,
causing an accumulation not only of sphingomyelin but also
of glycosphingolipids, sphingosine and others in multilamel-
lar storage bodies [76].
There are many other related and associated genetic dis-
eases, Metachromatic Leukodystrophy caused by a deficiency
of arylsulfatase A, Krabbe disease or globoid cell leukodys-
trophy caused by a deficiency of galactosylceramide-β-gala-
ctosidase and Farber disease caused by a deficiency of lyso-
somal acid ceramidase causing storage of excess ceramide in
the lysosomes. For further details of these and other sph-
ingolipid metabolic diseases, refer to an excellent review by
Kolter and Sandhoﬀ [77].
4.2. Hereditary Sensory Neuropathy. Clinical disorders are
also associated with alterations in SPT activity, although a
complete lack of SPT activity is predicted to be embryonically
lethal. The inherited disease hereditary sensory neuropathy
type I (HSN1) is a progressive degeneration of lower limb
sensory and autonomic neurons and has been associated
with mutations in the human LCB1 gene [78, 79]. LCB1
(SPTLC1) mutations confer dominant negative eﬀects on
SPT, thus substantially reducing SPT activity and hence the
rate of de novo synthesis of sphingolipids [80]. Recently,
point mutations have been found in the catalytic SPT subunit
(LCB2 or SPTLC2) in patients suﬀering from HSN1. These
were confirmed to aﬀect SPT activity using an in vitro system.
No mutations were observed in the third (SPTLC3) subunit
in these patients [81].
Point mutations in the SPT complex also aﬀect SPT ac-
tivity in terms of substrate specificity and alanine can be used
instead of serine in the condensation with palmitoyl-CoA, re-
sulting in the formation and accumulation of 1-deoxy-sphin-
ganine in the serum of these patients [82].
4.3. Alzheimer’s Disease. A relatively recent discovery was the
highly altered sphingolipid metabolism in brain cells in Al-
zheimer’s disease [83]. The latest study has highlighted the
key role of an nSMase in the disease by promoting the dam-
aging eﬀects of fibrillar amyloid-β 1–42 peptide-activated
astroglia through ceramide production and thus apoptosis in
neuronal cells [84].
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In addition, SPT has been shown to be downregulated by
the amyloid precursor protein [85]. This novel physiological
function of the amyloid precursor protein suggests that SPT
and sphingolipid metabolism is involved in Alzheimer’s dis-
ease pathology.
4.4. Other Diseases. Obesity and its established association
with insulin resistance, type 2 diabetes, and cardiovascular
disease are directly and/or indirectly involved in the overac-
cumulation of long-chain fatty acids. The resulting surplus
to the storage capacity of adipose tissue results in deposition
in nonadipose tissues, such as the liver, muscle, heart, and
pancreatic islets. This leads to deleterious eﬀects, not only as
atherosclerosis, but excess lipids are also forced into alter-
native nonoxidative pathways resulting in the formation of
reactive lipid moieties, such as sphingolipids, that promote
metabolically relevant cellular dysfunction (lipotoxicity) and
programmed cell death (lipoapoptosis) [86–88].
5. Sphingolipid Biosynthesis:
An Attractive Drug Target
Due to the complexities of sphingolipid metabolism and
associated defects in a variety of tissue types and cell com-
partments, there is a significant challenge in the understand-
ing, diagnosis, and treatment of genetic diseases such as those
discussed above. However, clinical manipulation sphingoli-
pid metabolism will prove key in the treatment of these con-
ditions; in addition it is becoming clear that by inducing the
accumulation of proapoptotic ceramide, therapies for cancer
and infectious disease may be developed.
5.1. Sphingolipidoses. The general strategy to treating the in-
herited human diseases involving sphingolipid metabolism,
the sphingolipidoses is the restoration of the defective lyso-
somal degradation. These include enzyme replacement, het-
erologous bone marrow transplantation as a form of cell-
mediated therapy, gene therapy and the use of chemical
chaperones for enzyme-enhancement therapy. An alterna-
tive strategy is the reduction of substrate influx into the
lysosomes using substrate reduction (substrate deprivation)
therapy ([77] and references therein).
5.2. Cancer. The roles of ceramide in diverse cellular res-
ponses to stress, particularly apoptosis, has been discussed
above and as mentioned elevated ceramide often result from
treatment with anticancer drugs and also irradiation. There-
fore the manipulation of sphingolipid biosynthesis and ho-
meostasis to elevate ceramide levels and induce programmed
cell death is a viable strategy for anticancer therapies [89].
Conversely, dysregulation of ceramidemetabolism aﬀects the
cellular response to chemotherapy or other anticancer regi-
mens by rendering the cells more resistant to killing; in these
cases therapeutic manipulation of ceramide metabolism
could overcome this resistance [90, 91]. Further develop-
ments in the manipulation of sphingolipid metabolism as an
anticancer strategy will undoubtedly follow with the break-
through discovery that FTY720, a water-soluble sphingosine
analogue eﬀective in many cancer models which acts by
downregulating nutrient transporter proteins in cancer cells
at least partially via ceramide generation [92]. The resulting
starvation induces a homeostatic autophagy selectively in
cancer cells sensitive to nutrient limitation, while normal
cells have the ability to adapt and survive by becoming qui-
escent. Notably AAL-149, an FTY720 analogue, similarly kills
patient-derived leukaemic cells, but not cells of healthy do-
nors, without the dose-limiting toxicity of FTY720. Thus, by
targeting the sphingolipid metabolism of cancer cells rather
than any specific oncogenic defect, such compounds should
have potent activity against a range of tumours, particularly
if applied in combination with inhibitors of autophagy.
5.3. Pathogens. The essential functions of sphingolipids,
coupled with the divergence of the biosynthetic pathway
between mammals and eukaryotic pathogens have resulted
in the investigation of the biosynthetic enzymes as possible
drug targets for antifungal and antiprotozoals. Consequently,
inhibitors of many of the steps in sphingolipid biosynthesis
have been described [2, 43]. Before the synthesis of ceramide/
phytoceramide the sphingolipid biosynthetic pathway is
largely conserved across evolution. At least in part because of
this, all the inhibitors identified as targeting fungal enzymes
in this part of the biosynthetic pathway are nonselective and
inhibit the mammalian orthologues [43]. This has curtailed
their clinical application as anti-fungal agents, for example
fumonisin B1 which inhibits the fungal phytoceramide syn-
thase demonstrated mammalian toxicity [93]. In contrast the
post-ceramide divergence represented by the absence of IPC
synthase and inositol-based sphingolipids in mammalian
cells, highlights the therapeutic potential of inhibitors tar-
geting fungal IPC synthases. Such inhibitors could result in
selective antifungal drugs with minimal host toxicity. Addi-
tionally, the identification and isolation of functional ortho-
logues of the fungal enzyme in the kinetoplastid protozoan
parasites (Leishmania spp., Trypanosoma brucei and Try-
panosoma cruzi) indicated that IPC synthase is a valid target
for antiprotozoal compounds [3]. One of the T. brucei sph-
ingolipid synthases, a novel bifunctional enzyme catalysing
the synthesis of both IPC and SM, is essential for parasite
growth and can be inhibited in vitro by the antifungal aure-
obasidin A at low nanomolar concentrations [43]. As the
causative agent of Chagas’ disease, Trypanosoma cruzi has a
complex lifecycle with an essential intracellular stage in ver-
tebrate hosts, in addition to an extracellular existence in an
insect vector. Necessary to persistence of the lifecycle is the
synthesis of surface glycosylphosphatidylinositol (GPI) an-
chored glycoconjugates, meaning that the biosynthesis of
GPI anchors is attractive target for new therapies against
Chagas’ disease [93]. As many T. cruzi GPI anchors contain
IPC as the lipid portion, the sole IPC synthase is highlighted
as a new therapeutic target for Chagas disease.
To date only the natural compounds—aureobasidin A
[33, 94, 95], Khafrefungin [94], and Rustmicin [96, 97] have
been reported as potent inhibitors of the fungal IPC synthase.
As discussed, there is an inhibitory eﬀect of aureobasidin A
against the Kinetoplastid enzyme orthologues [43, 98, 99],
although the specificity of this remains unclear [3, 100, 101].
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Unfortunately, further development of all the three known
inhibitors of IPC synthase has stalled either due to lack of
physical properties required for an acceptable pharmacoki-
netic profile [42, 102], or because their highly complex struc-
tures render chemical synthesis challenging. Moreover, the
few synthetic eﬀorts to modify or synthesise analogues that
have been reported, resulted in compounds with either re-
duced or no activity [103, 104]. What has proven more suc-
cessful however is the development of substrate (ceramide)
analogues, with targeted inhibition against the protozoal IPC
synthases in cellulo [105].
In addition to sphingolipid synthesis as a therapeutic tar-
get against parasitic protozoa, degradation of sphingolipids
similarly is an area providing new opportunities for anti-
protozoal compounds. Leishmania spp. use sphingolipid bio-
synthesis to generate ethanolamine (Etn), essential for the
survival and diﬀerentiation from procyclics to virulent meta-
cyclics [21]. A likely starting point for Etn production is the
degradation of IPC, and a putative neutral SMase and/or IPC
hydrolase (IPCase), designated ISCL was identified in the
L. major genome [106]. ISCL showed much greater activity
against non-self SM over IPC, suggesting a role in host SL
degradation confirmed by ISCL null mutants failing to in-
duce lesions in susceptible BALB/c mice. Further investiga-
tion revealed that host SL catabolism by Leishmania was
essential to resist the harsh acidic environment in the phagol-
ysosomes of macrophages [107]. These findings reveal that
SL catabolism, as well as anabolism, by Leishmania is nec-
essary for proliferation of the parasite in the mammalian
host, making the ISCL enzyme an equally attractive target for
inhibition studies. Trypanosoma cruzi invades mammalian
cells by attaching and mimicking injury to the host plasma
membrane, inducing a repair process that involves the
Ca2+-dependent exocytosis of lysosomes [108]. As host acid
sphingomyelinase (aSMase) is delivered by lysosomes to
the plasma membrane, its ceramide-generating activity pro-
motes rapid endocytosis to internalise the seemingly dam-
aged membrane and the attached parasites. Consequently
any inhibition or reduction of this lysosomal aSMase blocks
T. cruzi invasion, though subsequent treatment with an ex-
tracellular sphingomyelinase can restore the infection to nor-
mal levels. In a similar approach it has been demonstrated
that inhibition of host cell SPT, and so sphingolipid biosyn-
thesis, by myriocin, suppresses hepatitis C virus replication
[109]. In addition, it has emerged that ceramide induces acti-
vation of double-stranded RNA-dependent protein kinase-
mediated antiviral response [110]. These recent findings sug-
gest that manipulation of host sphingolipid metabolism may
provide a new combined therapeutic strategy for treatment
of both protozoal and viral infections.
6. Perspective
Recent studies of the genetic, biochemical and cell biology of
sphingolipids have provided exciting new insights into their
function, regulation and control, allowing the consideration
of future manipulations to aid the fight against human
diseases including cancer and major fungal and parasitic
infections. In addition, this information may ultimately aid
the treatment of several rare genetic disorders (e.g. the
sphingolipidoses) and, perhaps, Alzheimer’s disease. How-
ever, in most cases these studies are at an early stage and fur-
ther work is required to establish proof of concept. This will
undoubtedly be achieved as progress towards a fuller under-
standing of the complex and multilayered metabolic path-
ways of sphingolipidmetabolism is realized, and as inhibitors
of the enzymes involved become available.
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